We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Gyros platform enters leading US Clinical Research Organization
News

Gyros platform enters leading US Clinical Research Organization

Gyros platform enters leading US Clinical Research Organization
News

Gyros platform enters leading US Clinical Research Organization

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Gyros platform enters leading US Clinical Research Organization"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Gyros AB, a leader in the automation of miniaturized immunoassays, confirmed today that CEDRA Corporation has become the first North American Clinical Research Organization to incorporate a Gyrolab™ xP workstation into their offering for the biopharmaceutical industry.

The workstation will be used specifically for ligand binding assays at CEDRA’s bioanalytical research laboratory in Austin, Texas. Conventional, multi-step assay formats will be transformed into fully automated, integrated procedures performed at the nanoliter scale thus substantially boosting efficiency and productivity.

William Nowatzke, Ph.D., Director, Ligand Binding Assay Group, CEDRA Corporation explained: “A key driver to our business is the dedication to staying on the forefront of technology.  This investment addresses key areas of speed, strength and specificity in instrumentation and represents our dedication to enhancing the capabilities offered to the biopharmaceutical research industry.  We are investing in the highest performance system available; its flow-through format shortens analysis time, reduces sample matrix effects and minimizes sample consumption.”
  
CEDRA joins a steadily increasing number of laboratories in biopharmaceutical, contract research and contract manufacturing companies that have recognized the unique advantages of the Gyros platform. Erik Walldén, CEO at Gyros, added: “We are extremely pleased that leaders in the biotherapeutic industry are acknowledging the significant gains in productivity offered by our immunoassay solution. In fact, we now have a substantial proportion of our clients running multiple systems. Our open technology format enables clients to transfer their established ELISA assays easily and smoothly onto a faster, more efficient platform and to develop and optimize new immunoassays within days rather than weeks.”

Advertisement